tiprankstipranks
Trending News
More News >
Wakamoto Pharmaceutical Co., Ltd. (JP:4512)
:4512
Japanese Market
Advertisement

Wakamoto Pharmaceutical Co., Ltd. (4512) Financial Statements

Compare
0 Followers

Wakamoto Pharmaceutical Co., Ltd. Financial Overview

Wakamoto Pharmaceutical Co., Ltd.'s market cap is currently ¥10.62B. The company's EPS TTM is ¥-3.125; its P/E ratio is 159.96; and it has a dividend yield of 0.98%. Wakamoto Pharmaceutical Co., Ltd. is scheduled to report earnings on August 1, 2025, and the estimated EPS forecast is ¥―. See an overview of income statement, balance sheet, and cash flow financials.
Mar 25Mar 24Mar 23Mar 22Mar 21
Income Statement
Total Revenue¥ 7.79B¥ 7.74B¥ 8.66B¥ 8.38B¥ 8.89B
Gross Profit¥ 3.62B¥ 3.54B¥ 4.11B¥ 4.36B¥ 4.49B
Operating Income¥ -457.80M¥ -195.51M¥ 141.47M¥ -13.39M¥ -754.95M
EBITDA¥ 438.68M¥ 504.84M¥ 575.81M¥ 755.52M¥ -218.12M
Net Income¥ 64.44M¥ 108.96M¥ 138.26M¥ 238.54M¥ -601.86M
Balance Sheet
Cash & Short-Term Investments¥ 2.95B¥ 3.66B¥ 3.88B¥ 3.23B¥ 2.84B
Total Assets¥ 15.00B¥ 15.42B¥ 15.71B¥ 14.95B¥ 14.57B
Total Debt¥ 100.00M¥ 130.73M¥ 137.79M¥ 129.14M¥ 171.20M
Net Debt¥ -2.85B¥ -3.53B¥ -3.74B¥ -3.10B¥ -2.67B
Total Liabilities¥ 3.39B¥ 3.39B¥ 3.80B¥ 3.47B¥ 3.19B
Stockholders' Equity¥ 11.61B¥ 12.03B¥ 11.91B¥ 11.48B¥ 11.39B
Cash Flow
Free Cash Flow¥ -1.04B¥ -663.02M¥ 420.76M¥ -28.97M¥ -318.82M
Operating Cash Flow¥ -592.45M¥ -107.34M¥ 631.92M¥ 339.17M¥ 163.44M
Investing Cash Flow¥ -13.50M¥ -2.35M¥ 17.13M¥ 50.57M¥ -199.51M
Financing Cash Flow¥ -103.94M¥ -104.99M¥ -1.61M¥ -1.62M¥ -3.83M
Currency in JPY

Wakamoto Pharmaceutical Co., Ltd. Earnings and Revenue History

Wakamoto Pharmaceutical Co., Ltd. Debt to Assets

Wakamoto Pharmaceutical Co., Ltd. Cash Flow

Wakamoto Pharmaceutical Co., Ltd. Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis